ScripFollowing the conclusion within the past 20 months of two major deals in oncology potentially worth close to $13bn, Daiichi Sankyo Co., Ltd. is reorganizing its global structure in this disease area
ScripGo back a few years and Daiichi Sankyo Co., Ltd. was very heavily reliant commercially on its cardiovascular franchise, mostly the antihypertensive olmesartan (sold as Olmetec and others) and the an
ScripDaiichi Sankyo Co. Ltd. has said it is not in talks to sell off its over-the-counter products subsidiary, following a media report in Japan that the operation might be divested for around $900m. A re
ScripIn line with an increased focus on its oncology operations, which are now moving towards commercialization, Daiichi Sankyo Co. Ltd. is realigning its R&D activities in Japan and taking other steps t